Arsenic methylation, oxidative stress and cancer-is there a link?

Journal of the National Cancer Institute

Volumn 101, Issue 24, 2009, Pages 1660-1661

  Hughes, Michael F ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENIC ACID; ARSENIC TRIOXIDE; CACODYLIC ACID; METHANEARSONIC ACID; TRIMETHYLARSINE OXIDE;

CARCINOGENICITY; DNA DAMAGE; EDITORIAL; ENVIRONMENTAL EXPOSURE; HUMAN; METHYLATION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ARSENITES; CARCINOGENS; CELLS, CULTURED; DNA DAMAGE; DNA METHYLATION; ENZYME INHIBITORS; EPITHELIAL CELLS; HUMANS; MALE; METHYLTRANSFERASES; NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; PHENOTYPE; POLYMORPHISM, GENETIC; PROSTATE; RATS; SODIUM COMPOUNDS;

EID: 72649093249     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp437     Document Type: Editorial

References (30)

1. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans:Some Drinking-Water Disinfectants and Contaminants, Including Arsenic. Vol 84. Lyon. France:IARC; 2004.
2. National Research Council. Arsenic in Drinking Water. Washington, DC:National Academy Press; 1999.
3. National Research Council. Arsenic in Drinking Water 2001 Update. Washington, DC:National Academy Press; 2001.
4. Ng JC. Wang J. Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere. 2003; 52(3):1353-1359.
5. Wanibuchi H. Salim EI. Kinoshita A. et al. Understanding arsenic carci-nogenicity by the use of animal models. Toxicol Appl Pharmacol. 2004; 198(3):366-376.
6. Wei M. Wanibucvhi H. Morimura K. et al. Carcinogenicity of dimethy-larsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis. 2002; 23(3):1387-1397.
7. Arnold LL. Eldan M. Nyska A. et al. Dimethylarsinic acid:results of chronic toxicity/oncogenicity studies in F344 rats and in B6C3F1 mice. Toxicology. 2006; 223(3-2):82-100.
8. Waalkes MP. Liu J. Diwan BA. Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol. 2007; 222(3):271-280.
9. Challenger F. Biological methylation. Chem Rev. 1945; 36(3):315-361.
10. Vahter M. Mechanisms of arsenic biotransformation. Toxicology. 2002; 181-182:211-217.
11. Lu M. Wnag H. Li XF. Arnold LL. Cohen SM. Le XC. Binding of dimethylarsinous acid to cys-13alpha of rat hemoglobin is responsible for the retention of arsenic in rat blood. Chem Res Toxicol. 2007; 20(3):27-37.
12. 50 in hamsters and in vitro inhibition of pyruvate dehydro-genase. Chem Res Toxicol. 2001; 14(3):651-656.
13. Petrick JS. Ayala-Fierro F. Cullen WR. et al. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol. 2000; 163(3):203-207.
14. Styblo M. Del Razo LM. Vega L. et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol. 2000; 74(3):289-299.
15. Le XC. Ma M. Lu X. et al. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect. 2000; 108(31):1015-1018.
16. Del Razo LM. Styblo M. Cullen WR. et al. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol. 2001; 174(3):282-293.
17. Thomas DJ. Li J. Waters SB. et al. Arsenic (+3 oxidation state) methyl-transferase and the methylation of arsenicals. Exp Biol Med (Maywood). 2007; 232(3):3-13.
18. Kojima C. Ramirez DC. Tokar EJ. et al. Requirement of arsenic biomethyla-tion for oxidative DNA damage. J Natl Cancer Inst. 2009; 101(34):1670-1681.
19. Drobna Z. Waters SB. Devesa V. et al. Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase. Toxicol Appl Pharmacol. 2004; 207(3):147-159.
20. Rossman TG. Mechanisms of arsenic carcinogenesis:an integrated approach. Mutat Res. 2003; 533(3-2):37-65.
21. Hughes MF. Kitchin KT. Arsenic, oxidative stress, and carcinogenesis. In:Singh KK. eds. Oxidative Stress, Disease and Cancer. London, UK:Imperial College Press; 2006:825-850.
22. Lin S. Cullen WR. Thomas DJ. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol. 1999; 12(30):924-930.
23. Yamanaka K. Takabayashi F. Mizoi M. et al. Oral exposure of dimethylar-sinic acid, a main metabolite of inorganic arsenics, in mice leads to an increase in 8-oxo-2 ' deoxyguanosine level, specifi cally in the target organs for arsenic carcinogenesis. Biochem Biophys Res Commun. 2001; 287(3):66-70
24. An Y. Gao Z. Wang Z. et al. Immunohistochemical analysis of oxidative DNA damage in arsenic-related human skin samples from arsenic-contaminated area of China. Cancer Lett. 2004; 214(3):11-18.
25. Platanias LC. Biological responses to arsenic compounds. J Biol Chem. 2009; 284(38):18583-18587.
26. Yamauchi H. Yamamura Y. Metabolism and excretion of orally administrated arsenic trioxide in the hamster. Toxicology. 1985; 34(3):113-121.
27. Huang C. Ke Q. Costa M. et al. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem. 2004; 255(3-2):57-66.
28. Del Razo LM. Quintanilla-Vega B. Brambila-Colombres E. Calderon-Aranda ES. Manno M. Albores A. Stress proteins induced by arsenic. Toxicol Appl Pharmacol. 2001; 177(3):132-148.
29. Schlawicke Engstrom K. Broberg K. Concha G. et al. Genetic polymorphisms infl uencing arsenic metabolism:evidence from Argentina. Environ Health Perspect. 2007; 115(3):599-605.
30. Valenzuela OL. Drobna Z. Hernandez-Castellanos E. et al. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol Appl Pharmacol. 2009; 239(3):200-207.